Facts & Figures
Research Funding Information
Fiscal Year 2015, Psychiatry
Psychiatry - $9,057,968.00
Glahn, David PhD
Gene Networks Influencing Psychotic Dysconnectivity in African Americans. Yale University.
Choi, Jimmy PhD
Intrinsic Motivation and Learning in Schizophrenia. NIH.
Pearlson, Godfrey M.D.
“Functional Neuroimaging of Alcoholism Vulnerability: Glutamate, Reward, Impulsivity, and Payloyian-to-Instrumental Transfer (PIT), Part II – Saracatinib” Yale University.
2 R01 MH077945-05A1 entitled 3/5 Bipolar-Schizophrenia Network for Intermediate Phenotypes 2. Yale University.
Pearlson, Godfrey, M.D./ Stevens, Michael PhD
Neuroscience of Marijuana Impaired Driving. Yale University.
Stevens, Michael PhD
Neural Architecture of Emotion Regulation, Adolescent Development and Depression. NIH.
Psychiatry - $22,070.97
Choi, Jimmy PhD
Neural Basis of Intrinsic Motivation in Schizophrenia. NARSAD.
Psychiatry - $2,583,308.50
Malik, Salma M.D.
A Multicenter, Double-blind, Placebo- and Active-Controlled Parallel-Group Evaluation of the Safety and Efficacy of Vilazodone in Pediatric patients With Major Depressive Disorder (VLZ-MD-22). Forest Research Institute.
An Open-label Long-term Safety Study of Vilazodone in Pediatric Patients with Major Depressive Disorder. Forest Laboratories.
Tolin, David PhD
Field Testing of an Online Diagnostic Checklist for Children, Adolescents, and Young Adults. Mindyra, LLC.
Winokur, Andrew M.D./John Goethe, M.D.
A Phase 3 Efficacy and Safety Study of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder (the FORWARD-4 Study) ALK5461-205. Premier Research.
A Phase 3 Multicenter Study of the Long-term Safety and Tolerability of ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy (the FORWARD-2 Study) (ALKS5461-208). INC Research, LLC.
A Prospective, Longitudinal, Observational Study to Evaluate Potential Predictors of Relapse in Subjects with Major Depressive Disorder Who Have Responded to Antidepressant Treatment (OBSERVEMDD0001). Janssen Research & Development, LLC.
An 8-week, randomized, phase 2, double-blind, Sequential parallel-group comparison study of Two dose levels of pf-06372865 compared to Placebo as an adjunctive treatment in Outpatients with inadequate response to Standard of care for generalized anxiety Disorder (Protocol # B7431007). InVentiv Clinical, LLC.
A Phase 2a Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-center Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Subjects with Social Anxiety Disorder. Janssen Research & Development, LLC.
A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression. Janssen Research & Development, LLC.
Psychiatry - $21,753.00
Diefenbach, Gretchen PhD
Treating Anxiety with Cognitive Bias Modification Combined with Transcranial Magnetic Stimulation. HH-Endowment Funds. (OC)-129513.
Hallion, Lauren, PhD
Cognitive Control as a Mechanism and Intervention Target in Emotional Disorders. HH-Endowment Funds (OC)-129513.
Ng, Janet PhD
A mindfulness-based weight loss maintenance intervention to enhance bariatric surgery outcomes. HH-Endowment Funds (OC)-129513.
Psychia - $0.00
Barrett, Jennifer B.A.
Olin Neuropsychiatry Research Center Volunteer Research Registry.
Emadi, Nazli, MD, PhD
Prediction of cognitive decline by 3MS and MoCA compared to brain volumetric MRI in Alzheimer’s disease.
Pearlson, Godfrey, M.D.
“Functional Neuroimaging of Alcoholism Vulnerability: Glutamate, Reward, Impulsivity, and Payloyian-to-Instrumental Transfer (PIT), Part II – Saracatinib”.
Bi-directional data sharing of neuroimaging data with the Human Connectome Project.
Peck, Caleb Psy.D.
Can the MMPI-2RF differentiate malingering from conversion disorders in a known samples study?
Tolin, David PhD
Development and Validation of the Broad Assessment Questionnaire.
Young, Kevin PhD
Using psychological testing to enhance prediction of lethal suicide attempts.
Comparing Autism Spectrum Disorders and Psychosis using the Rorschach: A Feasibility Study.